IRB #

IRB00005669

Title

A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients with Chronic Myelomonocytic Leukemia (CMML)

Principal Investigator

Kim-Hien Dao

Study Purpose

The purpose of this study is to find out what effects, good and/or bad, the study drug has on CMML. This research is also being done to develop biomarkers that can be used to see how well the body responds to treament with 5-azacitidine.

Medical Condition(s)

Myeloid Leukemia

Eligibility Criteria

*Subjects should have a diagnosis of CMML as defined by WHO criteria.
*Subjects should be age 18 or older.
*Subjects should not have clinically significant heart disease.
*Subjects should not have progression to AML.
*Other active malignancies (except basal cell carcinoma of the skin and carcinoma in situ of the cervix).

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

2 years or 24 cycles

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

University of Utah-Huntsman Cancer Institute

Recruitment End

Compensation Provided

No